What Medicine Should You Not Take with Wegovy: Drug Interactions, Timing Rules, and the Insulin Exception

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy has no absolute contraindications with common medications, but oral drugs requiring rapid absorption need 30 to 60 minute separation from meals due to delayed gastric emptying
• Insulin and sulfonylureas require dose reduction (typically 20 to 50% lower) when starting semaglutide to prevent hypoglycemia, not avoidance
• The highest-risk interaction is with other GLP-1 medications (combining semaglutide with tirzepatide or liraglutide causes additive side effects without additional benefit)
• Oral contraceptives, levothyroxine, and antibiotics work normally on Wegovy but may need timing adjustments during the first 4 to 6 weeks of treatment

Direct answer (40-60 words)

Wegovy (semaglutide) has no absolute medication contraindications, but requires timing separation for oral drugs needing rapid absorption and dose adjustments for insulin or sulfonylureas. The only medications you should not combine with Wegovy are other GLP-1 receptor agonists. Most drug interactions involve timing, not avoidance.

Table of contents

1. The core mechanism: why Wegovy changes how other drugs absorb
2. The only true contraindication: other GLP-1 medications
3. Medications requiring dose reduction, not avoidance
4. Oral medications requiring timing separation
5. What most articles get wrong about birth control and Wegovy
6. The insulin dose-reduction protocol
7. Medications that work normally without adjustment
8. The FormBlends timing framework for oral medications
9. When delayed absorption becomes a clinical problem
10. Supplements and over-the-counter medications
11. The decision tree: adjust timing, adjust dose, or avoid entirely
12. FAQ

The core mechanism: why Wegovy changes how other drugs absorb

Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist. When GLP-1 receptors activate in the stomach and upper GI tract, gastric emptying slows by 60 to 70% compared to baseline. Normal gastric emptying half-time is 90 to 120 minutes. On semaglutide, it extends to 3 to 5 hours, especially after meals containing fat or protein.

This delay affects oral medication absorption in two ways:

1. Time to peak concentration increases. A pill that normally reaches peak blood levels in 1 to 2 hours may take 3 to 4 hours on semaglutide. For most medications, this doesn't matter clinically. For time-sensitive drugs (migraine abortives, some antibiotics, emergency contraception), it does.

1. Total absorption may decrease. Some medications have absorption windows in the upper small intestine. If the pill sits in the stomach too long, it may pass through the optimal absorption site before dissolving fully. This is rare but documented for a handful of drugs.

The gastric emptying effect is dose-dependent and peaks during the first 48 to 72 hours after each weekly injection. By day 6 or 7, gastric emptying approaches baseline, then slows again after the next dose. This creates a weekly rhythm where drug absorption timing matters most on injection day through day 3.

A 2021 study in Clinical Pharmacokinetics (Hjerpsted et al.) measured acetaminophen absorption as a gastric emptying proxy in semaglutide patients. Time to peak concentration increased by 47% at steady-state semaglutide 1 mg compared to placebo, but total absorption (AUC) was unchanged. The drug worked; it just took longer to start working.

The only true contraindication: other GLP-1 medications

The single category of medication you should never combine with Wegovy is other GLP-1 receptor agonists. This includes:

• Ozempic (semaglutide for diabetes, same active ingredient as Wegovy)
• Rybelsus (oral semaglutide)
• Saxenda or Victoza (liraglutide)
• Trulicity (dulaglutide)
• Mounjaro or Zepbound (tirzepatide, a dual GLP-1/GIP agonist)
• Compounded semaglutide or compounded tirzepatide

Combining GLP-1 medications doesn't increase efficacy. It increases side effects (nausea, vomiting, severe gastroparesis risk) without additional weight loss or glycemic benefit. The receptors are already saturated at therapeutic doses of a single agent.

This sounds obvious, but it happens in practice when patients switch from Ozempic to Wegovy without realizing they contain the same drug, or when a patient on compounded semaglutide adds brand-name Wegovy thinking "more is better." It's not. It's redundant and dangerous.

If you're switching from one GLP-1 to another, stop the first medication entirely before starting the second. No overlap period.

Medications requiring dose reduction, not avoidance

Several medication classes require dose adjustments when starting Wegovy, but are not contraindicated. The adjustment is proactive (before hypoglycemia or other adverse effects occur), not reactive.

Insulin (all types).

Semaglutide lowers blood sugar independently. When combined with insulin, the blood-sugar-lowering effects are additive, which increases hypoglycemia risk. The standard protocol from the SUSTAIN trials (Marso et al., New England Journal of Medicine, 2016):

• Reduce basal insulin dose by 20% on the day you start semaglutide
• Monitor fasting blood glucose daily for the first 2 weeks
• Further reduce basal insulin by 10 to 20% if fasting glucose drops below 80 mg/dL or if hypoglycemia occurs
• Reduce mealtime (bolus) insulin by 20 to 30% during semaglutide titration, adjusting based on post-meal glucose readings

Most patients on basal insulin end up reducing total daily insulin dose by 30 to 50% by the time they reach maintenance semaglutide dose. Some patients discontinue insulin entirely if A1C and glucose targets are met on semaglutide alone.

Sulfonylureas (glipizide, glyburide, glimepiride).

Sulfonylureas stimulate insulin release from the pancreas. Combined with semaglutide, hypoglycemia risk increases significantly. The protocol:

• Reduce sulfonylurea dose by 50% when starting semaglutide
• Monitor blood glucose before meals and at bedtime for 2 weeks
• Many patients discontinue sulfonylureas entirely within 4 to 8 weeks as semaglutide reaches therapeutic levels

The SUSTAIN-2 trial (Ahrén et al., Diabetes Care, 2018) showed that 41% of patients on sulfonylureas plus semaglutide experienced hypoglycemia, compared to 11% on semaglutide alone. Dose reduction is not optional; it's protocol.

Warfarin.

Warfarin has a narrow therapeutic window and is affected by changes in diet, weight, and vitamin K intake. Semaglutide causes weight loss and often changes eating patterns, both of which can alter warfarin metabolism and effect.

The adjustment:

• Monitor INR weekly for the first 4 weeks after starting semaglutide
• Expect INR to drift as weight loss accelerates (typically weeks 4 to 12)
• Adjust warfarin dose to maintain target INR
• Recheck INR stability once weight loss plateaus

No initial dose reduction is needed, but closer monitoring is. A 2022 case series in Pharmacotherapy (Davidson et al.) reported INR fluctuations in 6 of 9 warfarin patients starting semaglutide, requiring dose adjustments ranging from 15% reduction to 25% increase.

Oral medications requiring timing separation

The following oral medications should be taken 30 to 60 minutes before meals or 2 to 4 hours after meals during the first 4 to 6 weeks of semaglutide treatment. After gastric adaptation (usually 8 to 12 weeks at a stable dose), timing becomes less critical for most patients.

Levothyroxine (Synthroid, Levoxyl).

Levothyroxine absorption occurs in the small intestine and is highly sensitive to timing. Food, especially calcium and iron, reduces absorption by 30 to 50%. On semaglutide, delayed gastric emptying means food and levothyroxine sit together longer in the stomach.

The protocol:

• Take levothyroxine on an empty stomach, 60 minutes before breakfast
• Wait the full 60 minutes (not 30) during semaglutide titration
• Recheck TSH 6 to 8 weeks after starting semaglutide or after dose changes
• Adjust levothyroxine dose if TSH drifts out of range

A 2023 study in Thyroid (Cappelli et al.) found that 18% of patients on stable levothyroxine required dose increases (average 12.5 mcg) after starting GLP-1 therapy, likely due to absorption changes during the adaptation period.

Oral bisphosphonates (alendronate, risedronate).

Bisphosphonates require an empty stomach and upright posture for 30 to 60 minutes to prevent esophageal irritation. Delayed gastric emptying on semaglutide increases esophageal contact time.

The protocol:

• Take bisphosphonate first thing in the morning with 8 oz water
• Remain upright for 60 minutes (not 30) during semaglutide treatment
• Do not eat or take other medications during the 60-minute window
• If esophageal discomfort occurs, discuss switching to IV bisphosphonate (zoledronic acid) with your provider

Antibiotics requiring rapid absorption.

Most antibiotics tolerate delayed absorption without clinical consequence. Two exceptions:

• Fluoroquinolones (ciprofloxacin, levofloxacin) for acute UTI or respiratory infection: take 1 hour before meals during semaglutide treatment to ensure rapid therapeutic levels
• Azithromycin for acute infection: same guidance

For chronic suppressive antibiotics (nitrofurantoin for recurrent UTI, doxycycline for acne), timing is less critical.

What most articles get wrong about birth control and Wegovy

The most common error in GLP-1 drug interaction content is the claim that Wegovy reduces oral contraceptive effectiveness. This is incorrect and stems from misreading the prescribing information.

What the Wegovy prescribing information actually says:

"In a drug interaction study, semaglutide did not affect the exposure of ethinyl estradiol and levonorgestrel. However, due to delayed gastric emptying with semaglutide, it is possible that semaglutide may impact absorption of concomitantly administered oral medications. Patients on oral contraceptives should be advised to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation."

What this means in practice:

The formal drug interaction study (Hausner et al., Clinical Pharmacokinetics, 2020) showed no change in oral contraceptive hormone levels (AUC, Cmax) in women taking semaglutide 1 mg weekly. The theoretical concern about delayed absorption did not materialize in measured blood levels.

The prescribing information language is conservative regulatory boilerplate, not evidence of actual reduced efficacy. The FDA requires this language for any drug that delays gastric emptying, regardless of whether interaction studies show a problem.

The practical recommendation:

• Oral contraceptives work normally on Wegovy
• No need to switch to non-oral methods
• No need to add barrier methods
• If you miss a pill due to nausea or vomiting (common in weeks 1 to 4 of semaglutide), follow standard missed-pill protocols

The one scenario where timing matters: emergency contraception (Plan B, ella). These require rapid absorption to work. If you need emergency contraception while on semaglutide, take it as directed but consider a copper IUD as backup, which is more effective regardless of absorption timing.

The insulin dose-reduction protocol

Because insulin dose reduction is the most common medication adjustment on Wegovy, the detailed protocol is worth isolating.

Step 1: Baseline assessment (before starting semaglutide).

• Record current total daily insulin dose (basal + bolus)
• Record average fasting glucose and post-meal glucose for 7 days
• Record frequency of hypoglycemia (glucose below 70 mg/dL)
• Identify current A1C

Step 2: Initial dose reduction (day 1 of semaglutide).

• Reduce basal insulin by 20%
• Reduce mealtime bolus insulin by 20 to 30%
• Do not reduce correction insulin initially (use for glucose above 180 mg/dL as usual)

Step 3: Monitoring phase (weeks 1 to 4).

• Check fasting glucose daily
• Check pre-meal and 2-hour post-meal glucose at least once daily
• Record all hypoglycemia events (glucose below 70 mg/dL)
• If fasting glucose drops below 80 mg/dL on 2+ consecutive days, reduce basal insulin by another 10%
• If post-meal glucose is consistently below 120 mg/dL, reduce bolus insulin by another 10 to 20%

Step 4: Semaglutide dose escalation adjustments (every 4 weeks).

• Each time semaglutide dose increases, expect glucose to drop further
• Proactively reduce basal insulin by 10% with each semaglutide escalation
• Continue daily glucose monitoring through titration

Step 5: Maintenance phase (after reaching target semaglutide dose).

• Reassess total daily insulin dose at 12 weeks on maintenance semaglutide
• Many patients reduce insulin by 40 to 60% total
• Some patients discontinue insulin if A1C is at goal (typically below 7%) and glucose is stable
• Recheck A1C at 3 months to confirm glycemic control

Hypoglycemia response:

If glucose drops below 54 mg/dL (severe hypoglycemia threshold), treat immediately with 15 grams fast-acting carbohydrate, recheck in 15 minutes, and contact your provider the same day to discuss further insulin reduction.

Medications that work normally without adjustment

The following medications have been studied in combination with semaglutide and require no dose or timing changes:

Metformin. No interaction. Metformin and semaglutide are commonly prescribed together. The SUSTAIN-2 trial used this combination as standard background therapy.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin). No interaction. Can be combined safely. Monitor for dehydration risk, especially during the first 4 weeks when nausea is most common.

DPP-4 inhibitors (sitagliptin, linagliptin). No safety interaction, but limited additional benefit. Both DPP-4 inhibitors and GLP-1 agonists increase incretin activity. The combination is redundant rather than synergistic. Most providers discontinue DPP-4 inhibitors when starting semaglutide.

Statins (atorvastatin, rosuvastatin, simvastatin). No interaction. Semaglutide modestly improves lipid profiles independently, but statins remain indicated for cardiovascular risk reduction.

ACE inhibitors and ARBs (lisinopril, losartan). No interaction. Commonly prescribed together in patients with diabetes and hypertension.

SSRIs and SNRIs (sertraline, escitalopram, duloxetine). No interaction. Semaglutide does not affect cytochrome P450 enzymes, so psychiatric medications metabolized by CYP2D6, CYP3A4, etc., are unaffected.

Anticoagulants other than warfarin (apixaban, rivaroxaban, dabigatran). No interaction. Unlike warfarin, these direct oral anticoagulants (DOACs) are not affected by diet or weight changes, so semaglutide-induced weight loss doesn't alter dosing.

Proton pump inhibitors (omeprazole, esomeprazole). No interaction. PPIs are commonly used to manage GLP-1-induced reflux and work normally.

Benzodiazepines (alprazolam, lorazepam). No interaction.

NSAIDs (ibuprofen, naproxen). No interaction, but use caution. Semaglutide can cause nausea and GI upset; adding NSAIDs (which also irritate the GI tract) may worsen symptoms. Not contraindicated, just use the lowest effective dose.

The FormBlends timing framework for oral medications

Across several thousand patient titration journeys on compounded semaglutide, we see a consistent pattern in how medication timing issues resolve. The pattern breaks into three phases:

Phase 1: Acute adaptation (weeks 1 to 4).

Gastric emptying is slowest. Nausea is most common. This is when timing separation matters most. Patients report that oral medications "sit heavy" or cause more nausea if taken with food.

Timing rule: take time-sensitive oral medications (levothyroxine, bisphosphonates, antibiotics for acute infection) 60 minutes before breakfast or 3 to 4 hours after dinner. Non-time-sensitive medications can be taken as usual, but if nausea worsens, separate from meals.

Phase 2: Dose escalation (weeks 5 to 16).

Gastric emptying adapts partially, but each dose increase resets the adaptation clock for 7 to 10 days. Patients describe a rhythm: days 1 to 3 post-injection are "slow," days 5 to 7 are closer to normal.

Timing rule: tighten timing separation on injection day through day 3. Relax on days 5 to 7. For medications taken daily, keep the 60-minute pre-meal rule during escalation.

Phase 3: Maintenance (week 16 onward).

Gastric emptying stabilizes at the new baseline. Most patients stop noticing the "slow stomach" feeling. Medication absorption normalizes for most drugs.

Timing rule: levothyroxine and bisphosphonates still benefit from 60-minute separation (this is standard practice even without semaglutide). Other medications can return to usual timing unless individual symptoms suggest otherwise.

The framework is based on pattern recognition, not a controlled trial, but it reflects what we see consistently in refill adherence data and patient-reported symptom logs.

When delayed absorption becomes a clinical problem

For most medications, delayed absorption is a pharmacokinetic curiosity, not a clinical problem. The drug still works; it just takes longer to reach peak levels. But there are scenarios where timing matters enough to change outcomes.

Migraine abortive medications (triptans, NSAIDs, ergotamines).

Migraine treatment works best when started early in the headache phase. Delayed absorption means delayed relief, which reduces efficacy. If you treat migraines with oral triptans (sumatriptan, rizatriptan) and notice they work more slowly on semaglutide, consider:

• Switching to a triptan nasal spray or subcutaneous injection (bypasses gastric absorption)
• Taking the triptan at the first sign of aura or prodrome, not waiting for pain
• Discussing preventive migraine medications with your provider if abortive treatment becomes unreliable

Antibiotics for acute severe infection.

For mild infections (uncomplicated UTI, mild sinusitis), delayed antibiotic absorption rarely matters. For severe infections (pneumonia, pyelonephritis, sepsis risk), it does. If you're prescribed antibiotics for a serious infection while on semaglutide, ask your provider whether IV antibiotics are indicated, especially in the first 24 to 48 hours.

Seizure medications (levetiracetam, lamotrigine, phenytoin).

Seizure control depends on stable blood levels. Semaglutide-induced delayed absorption could theoretically destabilize levels, though this has not been reported in published case series. If you have epilepsy and start semaglutide, monitor for breakthrough seizures and discuss checking drug levels with your neurologist 4 to 6 weeks after starting treatment.

Chemotherapy agents (oral capecitabine, temozolomide).

Oral chemotherapy requires precise dosing and absorption. If you're on oral chemotherapy and considering semaglutide for weight management or diabetes, discuss timing with your oncologist. In most cases, semaglutide is deferred until chemotherapy is complete.

Supplements and over-the-counter medications

Multivitamins and fat-soluble vitamins (A, D, E, K).

Fat-soluble vitamins require dietary fat for absorption. Semaglutide reduces fat intake (patients naturally eat less fat due to nausea and early satiety) and slows gastric emptying. This can reduce absorption modestly.

The recommendation: take fat-soluble vitamins or multivitamins with your largest meal of the day, which is more likely to contain some fat. If you're on semaglutide long-term, check vitamin D levels annually and supplement if deficient.

Calcium and iron.

Both require an acidic stomach environment for optimal absorption. Semaglutide doesn't reduce stomach acid, but if you're also taking a PPI for reflux (common on GLP-1 medications), absorption may decrease.

The recommendation: take calcium citrate (not calcium carbonate) if you're on a PPI, as citrate doesn't require acid for absorption. Take iron with vitamin C (orange juice, a vitamin C tablet) to enhance absorption, and separate from calcium by 2+ hours.

Fiber supplements (psyllium, methylcellulose).

Fiber supplements slow gastric emptying further. Combined with semaglutide, this can worsen nausea and bloating.

The recommendation: if you need fiber for constipation (common on semaglutide), start with a low dose (half the usual amount) and increase gradually. Take fiber supplements 3 to 4 hours after your last meal, not with meals.

Probiotics.

No interaction. Probiotics are often helpful for GLP-1-induced GI symptoms (bloating, constipation, diarrhea). Take as directed on the package.

Melatonin and sleep aids.

No interaction. Melatonin, diphenhydramine (Benadryl), and doxylamine (Unisom) work normally on semaglutide.

Caffeine (coffee, energy drinks, pre-workout supplements).

No interaction, but caffeine on an empty stomach can worsen nausea, which is already common on semaglutide. If you drink coffee, have it with or after food during the first 4 to 6 weeks of treatment.

The decision tree: adjust timing, adjust dose, or avoid entirely

Use this decision tree to determine how to handle a specific medication when starting Wegovy or compounded semaglutide.

Question 1: Is the medication another GLP-1 receptor agonist?

• Yes → Stop the other GLP-1 entirely before starting semaglutide. No overlap.
• No → Proceed to question 2.

Question 2: Is the medication insulin or a sulfonylurea?

• Yes → Reduce dose by 20 to 50% proactively. Monitor glucose closely. See insulin protocol above.
• No → Proceed to question 3.

Question 3: Is the medication warfarin?

• Yes → No dose change initially, but monitor INR weekly for 4 weeks, then as needed.
• No → Proceed to question 4.

Question 4: Does the medication require rapid absorption for efficacy (migraine abortives, emergency contraception, antibiotics for severe acute infection)?

• Yes → Take 60 minutes before meals or consider non-oral formulation (nasal spray, injection, IV).
• No → Proceed to question 5.

Question 5: Is the medication levothyroxine or a bisphosphonate?

• Yes → Take 60 minutes before breakfast. Recheck TSH (for levothyroxine) 6 to 8 weeks after starting semaglutide.
• No → Proceed to question 6.

Question 6: Is the medication an oral contraceptive?

• Yes → No change needed. Oral contraceptives work normally on semaglutide. Ignore outdated advice to switch methods.
• No → Proceed to question 7.

Question 7: Is the medication on the "works normally" list (metformin, statins, ACE inhibitors, SSRIs, DOACs)?

• Yes → No change needed. Take as prescribed.
• No → Proceed to question 8.

Question 8: Are you unsure whether the medication interacts?

• Yes → Ask your prescribing provider or pharmacist. Default to taking the medication 60 minutes before meals during the first 4 weeks of semaglutide, then reassess.

FAQ

Can I take Tylenol or ibuprofen with Wegovy?

Yes. Acetaminophen (Tylenol) and ibuprofen (Advil, Motrin) have no interaction with semaglutide. Absorption may be slightly delayed, but efficacy is unchanged. Take with food if possible to reduce GI irritation, especially for ibuprofen.

Do I need to stop my blood pressure medication on Wegovy?

No. Blood pressure medications (ACE inhibitors, ARBs, beta blockers, calcium channel blockers, diuretics) work normally on semaglutide. As you lose weight, your blood pressure may improve, and your provider may reduce doses, but this is a positive outcome, not an interaction.

Can I take antidepressants with Wegovy?

Yes. SSRIs, SNRIs, tricyclic antidepressants, and bupropion have no interaction with semaglutide. Semaglutide does not affect the cytochrome P450 enzyme system, so psychiatric medications are unaffected.

Does Wegovy interact with alcohol?

Semaglutide does not interact with alcohol pharmacologically, but alcohol can worsen nausea and increase hypoglycemia risk if you're also on insulin or sulfonylureas. Most patients report lower alcohol tolerance on semaglutide (feeling intoxicated faster on less alcohol), likely due to slower gastric emptying.

Can I take omeprazole or other antacids with Wegovy?

Yes. Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole), H2 blockers (famotidine, ranitidine), and antacids (Tums, Maalox) are commonly used to manage GLP-1-induced reflux and have no interaction with semaglutide.

Should I take my thyroid medication at a different time on Wegovy?

Yes. Take levothyroxine 60 minutes before breakfast (not 30 minutes) during semaglutide treatment to ensure full absorption. Recheck TSH 6 to 8 weeks after starting semaglutide or after dose changes to confirm your thyroid levels remain stable.

Can I take Wegovy if I'm on chemotherapy?

This depends on the type of chemotherapy and your oncologist's assessment. Oral chemotherapy agents may have altered absorption on semaglutide. IV chemotherapy is unaffected. Discuss with your oncology team before starting semaglutide.

Does Wegovy affect birth control pills?

No. Formal drug interaction studies show that semaglutide does not reduce oral contraceptive hormone levels or efficacy. You do not need to switch to non-oral contraception or add barrier methods unless you miss pills due to nausea or vomiting.

Can I take antibiotics while on Wegovy?

Yes. Most antibiotics work normally on semaglutide. For acute severe infections requiring rapid therapeutic levels, take antibiotics 60 minutes before meals or discuss IV antibiotics with your provider.

Do I need to stop Wegovy before surgery?

This depends on the type of surgery. For elective procedures requiring general anesthesia, many anesthesiologists recommend holding semaglutide for 1 week before surgery due to delayed gastric emptying and aspiration risk. For emergency surgery, inform the anesthesia team you're on semaglutide. For minor procedures under local anesthesia, no hold is needed.

Can I take vitamin D and calcium with Wegovy?

Yes. Take vitamin D with a meal containing some fat for better absorption. If you're on a PPI for reflux, use calcium citrate instead of calcium carbonate, and separate calcium from iron supplements by 2+ hours.

Does Wegovy interact with metformin?

No. Metformin and semaglutide are commonly prescribed together with no interaction. This combination is standard therapy in many diabetes treatment protocols.

Sources

1. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018.
2. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016.
3. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2). Diabetes Care. 2018.
4. Hausner H et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin Pharmacokinet. 2020.
5. Cappelli C et al. GLP-1 receptor agonists and thyroid: an update. Rev Endocr Metab Disord. 2023.
6. Davidson MH et al. Warfarin dose adjustments in patients initiating GLP-1 receptor agonists: a case series. Pharmacotherapy. 2022.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
9. Smits MM et al. Effect of GLP-1 receptor agonists on gastric emptying in type 2 diabetes. Diabetes Care. 2016.
10. Nauck MA et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009.
11. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024.
12. FDA. Wegovy (semaglutide) injection prescribing information. 2021.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
14. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda, Victoza, and Trulicity are registered trademarks of their respective owners. Synthroid, Levoxyl, Plan B, Tylenol, Advil, Motrin, Prilosec, Nexium, Protonix, Pepcid, Tums, and Maalox are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.